Innogen, a Shanghai-based medical technology company, announced that its independently developed, human-derived, ...
Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The ...
Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.
Novo Nordisk faces challenges but its pipeline remains strong. Find out why NVO stock could deliver high double-digit returns ...
There are no studies documenting the percentage of doctors taking the drugs. But physicians “are a good litmus test for drugs ...
The popular weight-loss drugs known as GLP-1 receptor agonists, which were originally meant to treat diabetes, surged in ...
Big pharma’s pushing for PBS funding, and it’s kickstarting a shift to healthier snacks, smaller portions, and more ...
Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.
Telehealth provider Hims & Hers Health is defending its planned Super Bowl ad, which is styled as a political manifesto ...
Drug industry calls out telehealth company Hims & Hers' Super Bowl ad touting its knock-off weight loss medications.
NVO Investors with Losses Encouraged to Contact the FirmSan Francisco, California--(Newsfile Corp. - February 6, 2025) - Novo Nordisk A/S (NYSE: ...
Trademark prosecution data reveals how the rival healthcare companies are ensuring exclusivity internationally for their ...